SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-21-000106
Filing Date
2021-11-04
Accepted
2021-11-04 16:07:01
Documents
61
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20210930.htm   iXBRL 10-Q 1854499
2 EX-31.1 exhibit311q32021.htm EX-31.1 9998
3 EX-31.2 exhibit312q32021.htm EX-31.2 9996
4 EX-32.1 exhibit321q32021.htm EX-32.1 5661
5 EX-32.2 exhibit322q32021.htm EX-32.2 5768
  Complete submission text file 0001714899-21-000106.txt   6733702

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20210930.xsd EX-101.SCH 38749
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20210930_cal.xml EX-101.CAL 56569
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20210930_def.xml EX-101.DEF 169805
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20210930_lab.xml EX-101.LAB 493157
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20210930_pre.xml EX-101.PRE 321992
11 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20210930_htm.xml XML 1150916
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 211379927
SIC: 2836 Biological Products, (No Diagnostic Substances)